Skip to main content
Erschienen in: Endocrine 3/2016

18.04.2016 | Original Article

Association of multifocality, tumor number, and total tumor diameter with clinicopathological features in papillary thyroid cancer

verfasst von: Abbas Ali Tam, Didem Özdemir, Neslihan Çuhacı, Hüsniye Başer, Cevdet Aydın, Aylin Kılıç Yazgan, Reyhan Ersoy, Bekir Çakır

Erschienen in: Endocrine | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

Tumor multifocality is not an unusual finding in papillary thyroid carcinoma (PTC), but its clinical significance is controversial. In this study, we aimed to evaluate impact of multifocality, tumor number, and total tumor diameter on clinicopathological features of PTC. Medical records of 912 patients who underwent thyroidectomy and diagnosed with PTC were reviewed retrospectively. Patients were grouped into four according to number of tumoral foci: N1 (1 focus), N2 (2 foci), N3 (3 foci), and N4 (≥4 foci). The diameter of the largest tumor was considered the primary tumor diameter (PTD), and total tumor diameter (TTD) was calculated as the sum of the maximal diameter of each lesion in multicentric tumors. Patients were further classified into subgroups according to PTD and TTD. Multifocal PTC was found in 308 (33.8 %) patients. Capsular invasion, extrathyroidal extension, and lymph node metastasis were significantly higher in patients with multifocal tumors compared to patients with unifocal PTC. As the number of tumor increased, extrathyroidal extension and lymph node metastasis also increased (p = 0.034 and p = 0.004, respectively). The risk of lymph node metastasis was 2.287 (OR = 2.287, p = 0.036) times higher in N3 and 3.449 (OR = 3.449, p = 0.001) times higher in N4 compared to N1. Capsular invasion, extrathyroidal extension, and lymph node metastasis were significantly higher in multifocal patients with PTD ≤10 mm and TTD >10 mm than unifocal patients with tumor diameter ≤10 mm (p < 0.001, p < 0.001 and p = 0.001, respectively). There was no significant difference in terms of these parameters in multifocal patients with PTD ≤10 mm and TTD >10 mm and unifocal patients with tumor diameter >10 mm. In this study, increased tumor number was associated with higher rates of capsular invasion, extrathyroidal extension, and lymph node metastasis. In a patient with multifocal papillary microcarcinoma, TTD >10 mm confers a similar risk of aggressive histopathological behavior with unifocal PTC greater than 10 mm.
Literatur
1.
Zurück zum Zitat Y. Ito, M. Fukushima, M. Kihara, Y. Takamura, K. Kobayashi, A. Miya, A. Miyauchi, Investigation of the prognosis of patients with papillary thyroid carcinoma by tumor size. Endocr. J. 59, 457–464 (2012)CrossRefPubMed Y. Ito, M. Fukushima, M. Kihara, Y. Takamura, K. Kobayashi, A. Miya, A. Miyauchi, Investigation of the prognosis of patients with papillary thyroid carcinoma by tumor size. Endocr. J. 59, 457–464 (2012)CrossRefPubMed
2.
Zurück zum Zitat K.J. Kim, S.M. Kim, Y.S. Lee, W.Y. Chung, H.S. Chang, C.S. Park, Prognostic significance of tumor multifocality in papillary thyroid carcinoma and its relationship with primary tumor size: a retrospective study of 2309 consecutive patients. Ann. Surg. Oncol. 22, 125–131 (2015)CrossRefPubMed K.J. Kim, S.M. Kim, Y.S. Lee, W.Y. Chung, H.S. Chang, C.S. Park, Prognostic significance of tumor multifocality in papillary thyroid carcinoma and its relationship with primary tumor size: a retrospective study of 2309 consecutive patients. Ann. Surg. Oncol. 22, 125–131 (2015)CrossRefPubMed
3.
Zurück zum Zitat M. Iacobone, S. Jansson, M. Barczynski, P. Goretzki, Multifocal papillary thyroid carcinoma: a consensus report of the European Society of Endocrine Surgeons (ESES). Langenbecks Arch. Surg. 399, 141–154 (2014)CrossRefPubMed M. Iacobone, S. Jansson, M. Barczynski, P. Goretzki, Multifocal papillary thyroid carcinoma: a consensus report of the European Society of Endocrine Surgeons (ESES). Langenbecks Arch. Surg. 399, 141–154 (2014)CrossRefPubMed
4.
Zurück zum Zitat Y.K. So, M.W. Kim, Y.I. Son, Multifocality and bilaterality of papillary thyroid microcarcinoma. Clin. Exp. Otorhinolaryngol. 8, 174–178 (2015)CrossRefPubMedPubMedCentral Y.K. So, M.W. Kim, Y.I. Son, Multifocality and bilaterality of papillary thyroid microcarcinoma. Clin. Exp. Otorhinolaryngol. 8, 174–178 (2015)CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat H.J. Kim, H.K. Park, D.W. Byun, K. Suh, M.H. Yoo, Y.K. Min, S.W. Kim, J.H. Chung, Number of tumor foci as predictor of lateral lymph node metastasis in papillary thyroid carcinoma. Head Neck 37, 650–654 (2015)CrossRefPubMed H.J. Kim, H.K. Park, D.W. Byun, K. Suh, M.H. Yoo, Y.K. Min, S.W. Kim, J.H. Chung, Number of tumor foci as predictor of lateral lymph node metastasis in papillary thyroid carcinoma. Head Neck 37, 650–654 (2015)CrossRefPubMed
6.
Zurück zum Zitat A. Al Afif, B.A. Williams, M.H. Rigby, M.J. Bullock, S.M. Taylor, J. Trites, R.D. Hart, Multifocal papillary thyroid cancer increases the risk of central lymph node metastasis. Thyroid 25, 1008–1012 (2015)CrossRefPubMed A. Al Afif, B.A. Williams, M.H. Rigby, M.J. Bullock, S.M. Taylor, J. Trites, R.D. Hart, Multifocal papillary thyroid cancer increases the risk of central lymph node metastasis. Thyroid 25, 1008–1012 (2015)CrossRefPubMed
7.
Zurück zum Zitat J.S. Pyo, J.H. Sohn, G. Kang, D.H. Kim, J. Yun, Total surface area is useful for differentiating between aggressive and favorable multifocal papillary thyroid carcinomas. Yonsei. Med. J. 56, 355–361 (2015)CrossRefPubMedPubMedCentral J.S. Pyo, J.H. Sohn, G. Kang, D.H. Kim, J. Yun, Total surface area is useful for differentiating between aggressive and favorable multifocal papillary thyroid carcinomas. Yonsei. Med. J. 56, 355–361 (2015)CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat H.J. Kim, S.Y. Sohn, H.W. Jang, S.W. Kim, J.H. Chung, Multifocality, but not bilaterality, is a predictor of disease recurrence/persistence of papillary thyroid carcinoma. World J. Surg. 37, 376–384 (2013)CrossRefPubMed H.J. Kim, S.Y. Sohn, H.W. Jang, S.W. Kim, J.H. Chung, Multifocality, but not bilaterality, is a predictor of disease recurrence/persistence of papillary thyroid carcinoma. World J. Surg. 37, 376–384 (2013)CrossRefPubMed
9.
Zurück zum Zitat N. Qu, L. Zhang, Q.H. Ji, Y.X. Zhu, Z.Y. Wang, Q. Shen, Y. Wang, D.S. Li, Number of tumor foci predicts prognosis in papillary thyroid cancer. BMC Cancer 14, 914 (2014)CrossRefPubMedPubMedCentral N. Qu, L. Zhang, Q.H. Ji, Y.X. Zhu, Z.Y. Wang, Q. Shen, Y. Wang, D.S. Li, Number of tumor foci predicts prognosis in papillary thyroid cancer. BMC Cancer 14, 914 (2014)CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat D.S. Cooper, G.M. Doherty, B.R. Haugen, R.T. Kloos, S.L. Lee, S.J. Mandel, E.L. Mazzaferri, B. McIver, S.I. Sherman, R.M. Tuttle, Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16, 109–142 (2006)CrossRefPubMed D.S. Cooper, G.M. Doherty, B.R. Haugen, R.T. Kloos, S.L. Lee, S.J. Mandel, E.L. Mazzaferri, B. McIver, S.I. Sherman, R.M. Tuttle, Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16, 109–142 (2006)CrossRefPubMed
11.
Zurück zum Zitat F. Pacini, M. Schlumberger, H. Dralle, R. Elisei, J.W. Smit, W. Wiersinga, European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur. J. Endocrinol. 154, 787–803 (2006)CrossRefPubMed F. Pacini, M. Schlumberger, H. Dralle, R. Elisei, J.W. Smit, W. Wiersinga, European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur. J. Endocrinol. 154, 787–803 (2006)CrossRefPubMed
12.
Zurück zum Zitat J.D. Lin, T.C. Chao, C. Hsueh, S.F. Kuo, High recurrent rate of multicentric papillary thyroid carcinoma. Ann. Surg. Oncol. 16, 2609–2616 (2009)CrossRefPubMed J.D. Lin, T.C. Chao, C. Hsueh, S.F. Kuo, High recurrent rate of multicentric papillary thyroid carcinoma. Ann. Surg. Oncol. 16, 2609–2616 (2009)CrossRefPubMed
13.
Zurück zum Zitat D.W. Hosmer, S. Lemeshow, R.X. Sturdivant, Applied logistic regression, 3rd edn. (Wiley, New York, 2013)CrossRef D.W. Hosmer, S. Lemeshow, R.X. Sturdivant, Applied logistic regression, 3rd edn. (Wiley, New York, 2013)CrossRef
14.
15.
Zurück zum Zitat S.F. Kuo, S.F. Lin, T.C. Chao, C. Hsueh, K.J. Lin, J.D. Lin, Prognosis of multifocal papillary thyroid carcinoma. Int. J. Endocrinol. 2013, 809382 (2013)CrossRefPubMedPubMedCentral S.F. Kuo, S.F. Lin, T.C. Chao, C. Hsueh, K.J. Lin, J.D. Lin, Prognosis of multifocal papillary thyroid carcinoma. Int. J. Endocrinol. 2013, 809382 (2013)CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat B.H. Lang, C.Y. Lo, W.F. Chan, K.Y. Lam, K.Y. Wan, Staging systems for papillary thyroid carcinoma: a review and comparison. Ann. Surg. 245, 366–378 (2007)CrossRefPubMedPubMedCentral B.H. Lang, C.Y. Lo, W.F. Chan, K.Y. Lam, K.Y. Wan, Staging systems for papillary thyroid carcinoma: a review and comparison. Ann. Surg. 245, 366–378 (2007)CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat S.B. Edge, American joint committee on cancer: AJCC cancer staging manual, 7th edn. (Springer, New York, 2010) S.B. Edge, American joint committee on cancer: AJCC cancer staging manual, 7th edn. (Springer, New York, 2010)
18.
Zurück zum Zitat W. Wang, H. Wang, X. Teng, H. Wang, C. Mao, R. Teng, W. Zhao, J. Cao, TJ 3rd Fahey, L Teng, Clonal analysis of bilateral, recurrent, and metastatic papillary thyroid carcinomas. Hum. Pathol. 41, 1299–1309 (2010)CrossRefPubMed W. Wang, H. Wang, X. Teng, H. Wang, C. Mao, R. Teng, W. Zhao, J. Cao, TJ 3rd Fahey, L Teng, Clonal analysis of bilateral, recurrent, and metastatic papillary thyroid carcinomas. Hum. Pathol. 41, 1299–1309 (2010)CrossRefPubMed
19.
Zurück zum Zitat T.M. Shattuck, W.H. Westra, P.W. Ladenson, A. Arnold, Independent clonal origins of distinct tumor foci in multifocal papillary thyroid carcinoma. N. Engl. J. Med. 352, 2406–2412 (2005)CrossRefPubMed T.M. Shattuck, W.H. Westra, P.W. Ladenson, A. Arnold, Independent clonal origins of distinct tumor foci in multifocal papillary thyroid carcinoma. N. Engl. J. Med. 352, 2406–2412 (2005)CrossRefPubMed
20.
Zurück zum Zitat M. Bansal, M. Gandhi, R.L. Ferris, M.N. Nikiforova, L. Yip, S. Carty, Y. Nikiforov, Molecular and histopathologic characteristics of multifocal papillary thyroid carcinoma. Am. J. Surg. Pathol. 37, 1586–1591 (2013)CrossRefPubMed M. Bansal, M. Gandhi, R.L. Ferris, M.N. Nikiforova, L. Yip, S. Carty, Y. Nikiforov, Molecular and histopathologic characteristics of multifocal papillary thyroid carcinoma. Am. J. Surg. Pathol. 37, 1586–1591 (2013)CrossRefPubMed
21.
Zurück zum Zitat G. Tallini, D. Biase, C. Durante, G. Acquaviva, M. Bisceglia, R. Bruno, M.L.B. Reggiani, G.P. Casadei, G. Costante, N. Cremonini, L. Lamartina, D. Meringolo, F. Nardi, A. Pession, K.J. Rhoden, G. Ronga, M. Torlontano, A. Verrienti, M. Visani, S. Filetti, BRAF V600E and risk stratification of thyroid microcarcinoma: a multicenter pathological and clinical study. Mod. Pathol. 28, 1343–1359 (2015)CrossRefPubMed G. Tallini, D. Biase, C. Durante, G. Acquaviva, M. Bisceglia, R. Bruno, M.L.B. Reggiani, G.P. Casadei, G. Costante, N. Cremonini, L. Lamartina, D. Meringolo, F. Nardi, A. Pession, K.J. Rhoden, G. Ronga, M. Torlontano, A. Verrienti, M. Visani, S. Filetti, BRAF V600E and risk stratification of thyroid microcarcinoma: a multicenter pathological and clinical study. Mod. Pathol. 28, 1343–1359 (2015)CrossRefPubMed
22.
Zurück zum Zitat Q. Zhao, J. Ming, C. Liu, L. Shi, X. Xu, X. Nie, T. Huang, Multifocality and total tumor diameter predict central neck lymph node metastases in papillary thyroid microcarcinoma. Ann. Surg. Oncol. 20, 746–752 (2013)CrossRefPubMed Q. Zhao, J. Ming, C. Liu, L. Shi, X. Xu, X. Nie, T. Huang, Multifocality and total tumor diameter predict central neck lymph node metastases in papillary thyroid microcarcinoma. Ann. Surg. Oncol. 20, 746–752 (2013)CrossRefPubMed
23.
Zurück zum Zitat H. Qu, G.R. Sun, Y. Liu, Q.S. He, Clinical risk factors for central lymph node metastasis in papillary thyroid carcinoma: a systematic review and meta-analysis. Clin. Endocrinol. 83, 124–132 (2015)CrossRef H. Qu, G.R. Sun, Y. Liu, Q.S. He, Clinical risk factors for central lymph node metastasis in papillary thyroid carcinoma: a systematic review and meta-analysis. Clin. Endocrinol. 83, 124–132 (2015)CrossRef
24.
Zurück zum Zitat M. Mustafa, T. Kuwert, K. Weber, P. Knesewitsch, T. Negele, A. Haug, R. Linke, P. Bartenstein, D. Schmidt, Regional lymph node involvement in T1 papillary thyroid carcinoma: a bicentric prospective SPECT/CT study. Eur. J. Nucl. Med. Mol. Imaging 37, 1462–1466 (2010)CrossRefPubMed M. Mustafa, T. Kuwert, K. Weber, P. Knesewitsch, T. Negele, A. Haug, R. Linke, P. Bartenstein, D. Schmidt, Regional lymph node involvement in T1 papillary thyroid carcinoma: a bicentric prospective SPECT/CT study. Eur. J. Nucl. Med. Mol. Imaging 37, 1462–1466 (2010)CrossRefPubMed
Metadaten
Titel
Association of multifocality, tumor number, and total tumor diameter with clinicopathological features in papillary thyroid cancer
verfasst von
Abbas Ali Tam
Didem Özdemir
Neslihan Çuhacı
Hüsniye Başer
Cevdet Aydın
Aylin Kılıç Yazgan
Reyhan Ersoy
Bekir Çakır
Publikationsdatum
18.04.2016
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 3/2016
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-016-0955-0

Weitere Artikel der Ausgabe 3/2016

Endocrine 3/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Ist Fasten vor Koronarinterventionen wirklich nötig?

Wenn Eingriffe wie eine Koronarangiografie oder eine Koronarangioplastie anstehen, wird häufig empfohlen, in den Stunden zuvor nüchtern zu bleiben. Ein französisches Forscherteam hat diese Maßnahme hinterfragt.

Typ-2-Diabetes: Ernährungsunsicherheit vervierfacht Risiko für schwere Hypoglykämien

04.06.2024 Typ-2-Diabetes Nachrichten

Wenn ältere Menschen mit Typ-2-Diabetes Schwierigkeiten beim Beschaffen und Zubereiten von Mahlzeiten haben, geht dies mit einem deutlich gesteigerten Risiko für schwere Hypoglykämien einher.

Mehr Brustkrebs, aber weniger andere gynäkologische Tumoren mit Levonorgestrel-IUS

04.06.2024 Levonorgestrel Nachrichten

Unter Frauen, die ein Levonorgestrel-freisetzendes intrauterines System (IUS) verwenden, ist die Brustkrebsrate um 13% erhöht. Dafür kommt es deutlich seltener zu Endometrium-, Zervix- und Ovarialkarzinomen.

GLP-1-Agonist Semaglutid wirkt kardio- und nephroprotektiv

03.06.2024 Semaglutid Nachrichten

Der GLP-1-Agonist Semaglutid hat in der FLOW-Studie bewiesen, dass sich damit die Progression chronischer Nierenerkrankungen bei Patienten mit Typ-2-Diabetes bremsen lässt. Auch in kardiovaskulärer Hinsicht war die Therapie erfolgreich.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.